Parabolic Drugs Ltd

Parabolic Drugs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Parabolic Drugs Ltd

₹ 5.50 -4.35%
25 Jan 2021
parabolicdrugs.com BSE: 533211 NSE: PARABDRUGS
About

Parabolic Drugs engages in the manufacture and contract manufacture of active pharmaceutical ingredients (API) and API intermediates.

[ add key points ]
Website BSE NSE - BZ
  • Market Cap ₹ 34.0 Cr.
  • Current Price ₹ 5.50
  • High / Low ₹ /
  • Stock P/E
  • Book Value ₹ -138
  • Dividend Yield 0.00 %
  • ROCE -30.0 %
  • ROE %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Debtor days have improved from 272 to 146 days.

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -37.7% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Operating Profit
OPM %
Interest
Depreciation
Profit before tax
Tax %
EPS in Rs
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018
513 617 919 764 438 231 76 74 72
430 506 762 840 521 310 382 120 88
Operating Profit 83 112 157 -76 -83 -79 -306 -46 -16
OPM % 16% 18% 17% -10% -19% -34% -404% -63% -22%
5 15 4 3 13 1 0 6 4
Interest 38 41 64 73 84 99 108 11 9
Depreciation 6 18 31 55 68 73 67 54 35
Profit before tax 44 69 66 -201 -222 -250 -481 -105 -56
Tax % 22% 24% 23% -28% -40% 52% 1% 3% 3%
34 52 51 -144 -134 -380 -486 -108 -58
EPS in Rs 8.41 8.27 -23.35 -21.62 -61.47 -78.48 -17.46 -9.30
Dividend Payout % 0% 6% 3% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: -38%
3 Years: -32%
TTM: -3%
Compounded Profit Growth
10 Years: %
5 Years: 10%
3 Years: 23%
TTM: 47%
Stock Price CAGR
10 Years: -5%
5 Years: 26%
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: %

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018
Equity Capital 37 62 62 62 62 62 62 62 62
Reserves 121 317 367 234 114 -266 -752 -860 -917
421 474 555 780 842 957 971 978 983
111 214 332 162 204 190 287 303 281
Total Liabilities 690 1,067 1,315 1,239 1,222 943 569 484 409
130 163 188 334 331 395 371 349 326
CWIP 43 115 192 73 82 7 7 7 7
Investments 0 3 0 0 0 0 0 0 0
517 786 935 832 809 541 191 128 76
Total Assets 690 1,067 1,315 1,239 1,222 943 569 484 409

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018
-31 2 208 -119 31 -3 90 3 3
-87 -180 -206 -102 -30 -16 1 0 1
122 186 7 199 -8 16 -94 -4 -4
Net Cash Flow 4 8 9 -21 -7 -3 -2 -0 0

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018
Debtor Days 137 163 88 66 125 155 338 331 146
Inventory Days 239 278 237 167 364 451 45 60 91
Days Payable 82 138 149 59 187 146 103 416 463
Cash Conversion Cycle 294 303 176 175 301 460 279 -24 -226
Working Capital Days 255 263 154 207 299 448 -545 -777 -882
ROCE % 15% 14% -12% -13% -17% -72% -41% -30%

Shareholding Pattern

Numbers in percentages

Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020
37.79% 37.79% 37.79% 37.79% 37.79% 37.79% 37.79% 37.79% 37.79% 37.79% 37.79% 37.79%
8.06% 8.06% 8.06% 8.06% 8.06% 8.06% 8.06% 8.06% 8.06% 8.06% 8.06% 8.06%
0.58% 0.58% 0.58% 0.58% 0.58% 0.58% 0.58% 0.59% 0.58% 0.58% 0.58% 0.58%
53.57% 53.57% 53.57% 53.57% 53.57% 53.57% 53.57% 53.56% 53.57% 53.57% 53.57% 53.57%
No. of Shareholders 13,13213,09513,04412,95912,89912,82412,79412,86712,88513,22613,36013,652

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings